Conference Coverage Long-Term Treatment With Interferon Beta-1a or Glatiramer Acetate May Be Cost-Effective Read More
Conference Coverage 11-Year Data From BENEFIT Trial Support Early Treatment of Interferon Beta-1b for CIS Read More
Conference Coverage Computerized Cognitive Test May Be a Valid Assessment for Patients With MS Read More
Conference Coverage Age and DMT Exposure May Predict Conversion From Clinically Isolated Syndrome to MS Read More
Conference Coverage Alemtuzumab’s Benefits May Be Sustained for Three Years in Patients With MS Read More